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Abstract
BACKGROUND: 44Sc as a positron emitter can be an interest-
ing alternative to 68Ga (T½ = 67.71 min) due to its longer half-life 
(T½ = 3.97 h). Moreover, the b
– emitter 47Sc can be used for 
therapy when attached to the same biomolecule vectors. 
DOTA as a chelating agent has been proven suitable for the 
radiolabelling of peptides recognising tumour cell receptors 
in vivo with M3+ radiometals. DOTA-derivatized peptides have 
been successfully labelled with 90Y and 177Lu for therapy, 
and with 68Ga for PET imaging. However, published data on 
44Sc-labelled DOTA-biomolecules as potential PET radiotra-
cers are still very limited. The aim of this study was to com-
pare the affinity of natGa- and natSc-labelled DOTA-TATE to 
somatostatin receptors subtype 2 expressed in rat pancreatic 
cancer cell line AR42J. 
MATERIAL AND METHODS: The cold complexes of DOTA-TATE 
with natGa and natSc were synthesized and identified by HPLC 
and MS analysis and evaluated in vitro for competitive binding 
to cancer cell line AR42J expressing somatostatin receptors 
subtype 2 (sstr2).
 Comparison of receptor affinity 
of natSc-DOTA-TATE 
versus natGa-DOTA-TATE
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RESULTS: The IC50 values calculated from the displacement 
curve of [125I-Tyr11]-SST-14 were: 0.20 ± 0.18, 0.70 ± 0.20, 0.64 
± 0.22 and 0.67 ± 0.12 for natGa-DOTA-TATE, natSc-DOTA-TATE, 
DOTA-TATE, and [Tyr11]-SST-14 complexes, respectively, with 
the affinity lowering in the decreasing order:  natGa-DOTA-TATE 
> DOTA-TATE > Tyr11-SST-14 > natSc-DOTA-TATE.  
CONCLUSIONS: The binding affinity of natGa-DOTA-TATE ap-
peared higher than that of natSc-DOTA-TATE. Further in vitro and 
in vivo studies are needed to verify the influence of the chelated 
metal on the affinity and uptake of the respective radiolabelled 
compounds. This information might be crucial when the in vivo 
applications of peptides labelled with 68Ga and 44Sc for PET, as 
well as the use of 47Sc for radiotherapy are considered.
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Introduction
In recent yea rs peptide receptor radionuclide therapy (PRRT) 
has utilized synthetic peptides as vectors for radionuclides such 
as 90Y and 177Lu. This has been accomplished with the aid of 
positron emission tomography (PET), which involves the same 
vector biomolecules labelled with positron emitters, and was first 
demonstrated with 68Ga-labelled somatostatin (SST) analogues for 
diagnostic imaging of neuroendocrine tumours [1]. Since then 
growing interest in other positron emitters obtained in generator 
systems has been observed [2, 3]. The increasing availability of 
new radionuclides with diagnostic and therapeutic properties of-
fers new possibilities for individualized nuclear medicine options. 
44Sc is a positron emitter radionuclide [Eb+ max = 1475.4 keV, 
Er = 1157.0 keV (99.9%)] with a half life of 3.97 hours, which 
can be utilized for diagnostics with 47Sc as a matched pair for 
radiotherapy. Additionally, Grignon et al. [4] reported that 44Sc 
is an interesting radionuclide for nuclear medicine imaging using 
b+ – g coincidences. The use of 44Sc with a half-life more than 3 
times longer than that of 68Ga (T½ = 67.71 min) makes it an useful 
alternative for diagnostic purposes but also for dosimetry and 
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further therapy planning with the use of biomolecules labelled with 
the b– emitting 47Sc as radiotherapeutic agents [5]. The availability 
of 44Sc is also increasing [3, 6]. 
The chemistry of Sc3+ is similar to that of the lanthanides, 
and the “lanthanide like” elements. Due to its small ionic radius it 
is also chemically similar to aluminium and gallium [7]. The ther-
modynamic stability constant of the 1,4,7,10-teraazacyclodo-
decane-N,N’,N’,N’’’-teraacetic acid (DOTA) complex with Ga3+ is in 
the range from 21.3 to 26.1 [8, 9], with Sc3+ it is 27.0 [10], while the 
following values of 26.7, 23.9, 29.2, 25.95 have been reported for 
Lu3+ [7, 8, 11, 12]. All of the above values are similar as indicated 
from the data reported by Viola-Villegas and Doyle [13]. Hence 
chelators developed for the complexation of gallium, and the 
lanthanides can also be used for the complexation of scandium. 
Generally, small neuropeptides, such as somatostatin (SST) 
and gastrin releasing peptide (GRP)/bombesin (BN) analogues, 
labelled with g - and/or b–-emitting radionuclides are investigated 
for their ability to bind to receptors which are overexpressed in 
a variety of malignant tumours [14–16]. The affinity of the designed 
chelator-peptide construct to these receptors may vary depending 
on the metal incorporated into the complex [17].
The published results of the comparative in vitro and in vivo 
study of DOTA-BN[2-14]NH2 labelled with 
90Y and 177Lu as well 
as with 44Sc and 68Ga revealed differences in the in vitro and in vivo 
behaviour of these complexes, which could be attributed to the 
influence of metal on the complex receptor affinity [18, 19]. The 
present study is focused on the in vitro binding affinity of the M3+ 
type radiometals of Sc and Ga complexed with [DOTA,Tyr3,Thr8]
octreotide (DOTA-TATE), which is a clinically used somatostatin 
analogue [20, 21]. 
Material and methods
Chemicals 
DOTA-TATE was purchased from piChem (Austria). [125I-Tyr11]-
SST-14 and [Tyr11]-SST-14 were purchased from Perkin-Elmer 
Life and Analytical Sciences (USA). All other chemicals and 
materials were used as supplied and were of analytical grade 
unless otherwise stated.
Cold complexes of the peptide with natGa and natSc were syn-
thesized and identified by high pressure liquid chromatography 
(HPLC) and mass spectrometry (MS). 
High pressure liquid chromatography (HPLC)
The HPLC system for the quality control of the cold complex-
es was equipped with UV-VIS detector. The analysis was performed 
using a reverse phase C-18 Luna column (Phenomenex, USA). 
The mobile phase was a gradient of 0.1% TFA (Trifluoroacetic 
Acid)/H2O (Solvent A) and 0.1% TFA/Acetonitrile (ACN) (Solvent 
B). The elution scheme of solvent B was 0% for 2 min, increased 
to 40% from 2 to 9 min, remaining at 40% until 15 min, and then 
decreased to 0% in 3 min from 18 min to 23 remaining at 0%, at 
a flow rate of 0.6 ml/min.
Cold complexes of DOTA-TATE with natSc and natGa
The cold metal complexes of DOTA-TATE were synthesized 
and identified according to the previously described method [18]. 
Briefly, 100 μg of DOTA-TATE was dissolved in 250 μl ammonium 
acetate 0.4 M, pH 5, or 250 μl of ascorbic acid (100 mg/ml) 
was added. An appropriate amount of natScCl3 or 
natGaCl3 solu-
tion (1 mg/ml in 0.05 M HCl) was added to obtain a molar ratio of 
DOTA-TATE to metal 1:5. The sample was incubated at 95°C for 
25 minutes and left to cool down to room temperature. The cold 
complexes were analyzed by HPLC. The samples were purified 
from free metal by Solid Phase Extraction (SPE) using pre-con-
ditioned C-18 columns (100 mg resin, Sep-Pak, Waters), and the 
mobile phase consisted of 5 ml of ethanol and 5 ml of 0.9% NaCl. 
The samples were loaded on the cartridge followed by 5 ml 0.9% 
NaCl (to elute non-bound natSc or natGa) and by 3 ml pure methanol 
(natSc-DOTA-TATE or natGa-DOTA-TATE fraction). The cold complex 
fractions were then lyophilized under vacuum giving a light yellow 
powder in both cases. The purified samples were also analyzed by 
Electron Spray Ionization-Mass Spectrometry (ESI-MS). 
In vitro studies
Cell culture
The rat pancreatic cancer cell line AR42J expressing somato-
statin receptors subtype 2 (sstr2) was used for the in vitro experi-
ments. The cell line was cultured in RPMI-1640 (Gibco Invitrogen) 
supplemented with 10% foetal calf serum (Gibco Invitrogen), 
antibiotics (streptomycin, 100 μg/ml; penicillin, 100 U/ml; Sigma 
Aldrich), and glutamax (Gibco Invitrogen). The cells were kept in 
a humidified atmosphere at 37°C in 5% CO2. The cells were fed 
every 2 days and subcultured by trypsinization (0.05% Trypsin-ED-
TA, Gibco Invitrogen) when the cells covered about 80% of the 
surface in the flask. 
Saturation curve of 125I-Tyr11-SST-14
A saturation receptor assay for [125I-Tyr11]-SST-14 was performed 
prior to the binding affinity studies in order to determine the minimum 
concentration required for the saturation of sstr. The cells were 
seeded in 24-well plates (~8 × 104 cells/well) 48 h before the day 
of the experiment. On the day of the experiment the cells were in-
cubated at 37°C in 5% CO2 atmosphere for 90 min in the presence 
of increasing concentration of [125I-Tyr11]-SST-14 (0, 20000, 40000, 
60000, 80000, 100000, and 120000 cpm, corresponding to 0, 6.3, 
12.4, 18.9, 25.0, 31.5 and 37.8 pM, each in triplicate). At the comple-
tion of incubation the supernatant was collected and the cells were 
rinsed twice with 0.5 ml of cold phosphate-buffered saline (PBS). 
The cells underwent lyses by addition of 1N NaOH and incubation 
at 37°C/5% CO2 for 10 min. The radioactivity of the collected frac-
tions was measured in order to determine the minimum required 
concentration. Experiments were performed in triplicate.
Competitive binding studies
The in vitro receptor binding affinity and specificity of 
Tyr11-SST-14, DOTA-TATE and its cold complexes with natSc 
and natGa in AR42J cells were determined by a competitive 
displacement cell-binding assay using the iodinated analogue 
[125I-Tyr11]-SST-14 according to the method previously described 
[18]. Briefly, ~8 × 104 cells/well were seeded in 24-well plates 48 h 
before the day of the experiment. On the day of the experiment 
the cells were incubated at 37°C in 5% CO2 atmosphere for 1 h 
in the presence of 30,000–50,000 cpm of 125I-[Tyr11]-SST-14 and 
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increasing concentrations of the respective compound (from 1pM 
to 1μM), each in triplicate. Upon completion of the incubation, the 
reaction medium was aspirated and the cells were washed twice 
with cold PBS. The cells underwent lyses by additio n of 1 N NaOH 
and incubation at 37°C/5% CO2 for 10 min. The radioactivity of the 
collected fractions was measured in order to determine the IC50 
value (inhibitory concentration, 50%). 
Statistical methods 
The results were analyzed by non-linear regression analysis us-
ing GraphPad Prism (version TM, GraphPad software, San Diego 
California, USA). 
Results
Cold complexes of DOTA-TATE with natSc and natGa
The ESI-MS analysis of natGa-DOTA-TATE confirmed the 
presence of a single main complex at 764.2 [m/z]2+, which 
was in agreement with the calculated value (MW = 1505.3). The 
respective ESI-MS analysis of natSc-DOTA-TATE also confirmed 
the presence of a main peak at 761.5 [m/z]2+, being in agreement 
with the calculated value (MW = 1498.5). Figures 1 and 2 present 
the mass spectrum and the HPLC profile of natSc-DOTA-TATE, 
respectively. For the determination of the exact concentration of 
the cold complexes used for the in vitro assays, the BCA Protein 
Assay was used (BCA kit, Thermo Scientific). A calibration curve of 
DOTA-TATE of GMP grade was used for the determination of the 
concentration of DOTA-TATE (R&D grade), natSc-DOTA-TATE, and 
natGa-DOTA-TATE. The measured values were in good accordance 
with the calculated values.
Binding affinity studies
AR42J cancer cells were incubated with increasing concentra-
tions of [125I-Tyr11]-SST-14 in order to measure specific radioligand 
binding at equilibrium so as to perform the displacement affinity 
study of the [Tyr11]-SST-14, DOTA-TATE, natSc-DOTA-TATE and, 
natGa-DOTA-TATE. Based on the saturation curve, the minimum 
required amount of [125I-Tyr11]-SST14 in order for the receptors to 
be saturated was in the range of 9.5–15.8 pM (30,000–50,000 
cpm), calculated according to the specific activity of the iodinated 
compound (2200 Ci/mmol). 
The IC50 values calculated from the displacement curve of 
[125I-Tyr11]-SST-14 were: 0.20 ± 0.18, 0.70 ± 0.20, 0.64 ± 0.22 and 
0.67 ± 0.12 for natGa-DOTA-TATE, natSc-DOTA-TATE, DOTA-TATE, 
and [Tyr11]-SST-14 complexes, respectively, as listed in Table 1. 
The values indicate the following affinity pattern: natGa-DO-
TA-TATE > DOTA-TATE > Tyr11-SST-14 > natSc-DOTA-TATE. The 
respective displacement curves are presented in Figure 3. 
Discussion
Majkowska-Pilip and Bilewicz [10] evaluated the tri and tetraaza 
ligands for formation of macrocyclic complexes with Sc and 
compared them with analogous complexes of 177Lu and 68Ga. The 
authors concluded that DOTA is the most suitable ligand for binding 
scandium radionuclides to biomolecules. Viola-Villegas and Doyle 
Figure 2. RP-HPLC analysis of natSc-DOTA-TATE (UV absorbance 
monitored at 220 nm).
Figure 1. ESI-MS spectrum of natSc-DOTA-TATE.
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[13] indicated that there are differences in the crystal structure of 
DOTA with Ga and Sc, suggesting at the same time a higher stability 
of Sc-DOTA complex. On the other hand, it has been shown previ-
ously by Reubi et al. [17] that DOTA can be a very efficient chelator 
for Y, Lu, and Ga when coupled to somatostatin analogues. The in 
vitro comparison indicated that not only the peptide sequence and 
conjugated chelator, but to a large extent also the metal involved 
in the complex formation influences the affinity of the molecule to 
the somatostatin receptors. Our previously published comparison 
of the in vitro and in vivo properties of another DOTA-conjugated 
peptide, 90Y-DOTA-BN[2-14]NH2, 
177Lu-DOTA-BN[2-14]NH2, 
44Sc-DOTA-BN[2-14]NH2, and 
68Ga-DOTA-BN[2-14]NH2, revealed 
differences in the in vitro receptor affinity of these analogues (see 
Table 1) [18, 19]. These differences may be attributed to the struc-
tural changes in the radioligand molecule, which influence the 
interaction with the receptor. The introduction of a certain metal or 
its replacement by another one may provoke considerable altera-
tions in the in vivo binding affinity of a peptide to cell receptors and 
may have an important impact on the in vivo biodistribution of these 
radiopharmaceuticals. 
So far, there is no published data on 44Sc-labelled pep-
tides as PET tracer candidates in terms of in vitro and in vivo 
behaviour. Therefore, the main goal of this study was to evaluate 
the influence of the new radionuclide, 44Sc, on the receptor af-
finity of another DOTA derivatized peptide which is already well 
established, such as the somatostatin analogue DOTA-TATE 
[20, 21]. The 68Ga-DOTA-TATE was used in direct compari-
son since 68Ga complexes with DOTA chelated somatostatin 
analogues have been showing improved affinity to somatostatin 
receptor subtypes [17]. Considering the rather short half-life of 
68Ga, the 44Sc with 3.97 h half-life can be an interesting alternative 
for conjugation with biomolecules of longer metabolic half-life to 
allow late PET imaging.
Summary 
In the present study natGa-DOTA-TATE showed slightly higher 
binding affinity to sst receptors of the AR42J cell line than nat-
Sc-DOTA-TATE, and the IC50 values of the studied derivatives were 
decreasing in the order natGa-DOTA-TATE > DOTA-TATE > [Tyr11]-
SST-14 > natSc-DOTA-TATE. This relationship is in favour of Ga and 
is similar to the previously reported data for the DOTA-BN[2-14]NH2 
derivatives [18, 19]; however, the differences of affinity between 
Ga- and Sc-labelled DOTA-TATE are not so pronounced as they 
were in the case of  DOTA-BN[2-14]NH2. Therefore, further stu-
dies are needed to verify if the influence of Sc radionuclides on the 
peptide affinity to certain receptors is critical for their diagnostic 
or therapeutic utility.  
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